Abstract The increased life expectancy of people living with HIV-1 who are taking effective anti-retroviral therapeutics is now accompanied by increased Alzheimer's disease (AD)-like neurocognitive problems and neuropathological features such as increased levels of amyloid beta (Aβ) and phosphorylated tau proteins. Others and we have shown that HIV-1 Tat promotes the development of AD-like pathology. Indeed, HIV-1 Tat once endocytosed into neurons can alter morphological features and functions of endolysosomes as well as increase Aβ generation. Caffeine has been shown to have protective actions against AD and based on our recent findings that caffeine can inhibit endocytosis in neurons and can prevent neuronal Aβ generation, we tested the hypothesis that caffeine blocks HIV-1 Tat-induced Aβ generation and tau phosphorylation. In SH-SY5Y cells over-expressing wildtype amyloid beta precursor protein (AβPP), we demonstrated that HIV-1 Tat significantly increased secreted levels and intracellular levels of Aβ as well as cellular protein levels of phosphorylated tau. Caffeine significantly decreased levels of secreted and cellular levels of Aβ, and significantly blocked HIV-1 Tat-induced increases in secreted and cellular levels of Aβ. Caffeine also blocked HIV-1 Tat-induced increases in cellular levels of phosphorylated tau. Furthermore, caffeine blocked HIV-1 Tat-induced endolysosome dysfunction as indicated by decreased protein levels of vacuolar-ATPase and increased protein levels of cathepsin D. These results further implicate endolysosome dysfunction in the pathogenesis of AD and HAND, and by virtue of its ability to prevent and/or block neuropathological features associated with AD and HAND caffeine might find use as an effective adjunctive therapeutic agent.
Introduction
Human immunodeficiency virus-1 (HIV-1) continues to be a serious global health concern with more than 40 million people worldwide living with HIV-1 infection. Although effective antiretroviral therapies (ART) have increased the life span of people living with HIV-1 infection, HIV-1 infected individuals are now experiencing a family of HIV-1 associated neurocognitive disorders (HAND), the prevalence of which in the USA is greater than 50 % (Ellis et al. 2010; Heaton et al. 2010) . Increasingly, the incidence of Alzheimer's disease (AD)-like clinical symptomatology and neuropathological features such as increased levels of amyloid beta (Aβ) protein (Esiri et al. 1998; Nebuloni et al. 2001; Gelman and Schuenke 2004; Green et al. 2005; Achim et al. 2009; Clifford et al. 2009; Pulliam 2009; Xu and Ikezu 2009) and phosphorylated tau protein (Brew et al. 2005; Anthony et al. 2006; Patrick et al. 2011 ) are being noted in HIV-1 infected patients the vast majority of whom are taking ART.
HIV-1 transactivator of transcription (Tat) protein is a nonstructural transcriptional regulator essential for the replication of HIV-1. HIV-1 Tat can be transported across the blood-brain barrier from the systemic circulation (Kim et al. 2003; Banks et al. 2005) , can be secreted by infected macrophages and microglia, and has been detected in brain of patients with HIV-1 associated dementia (Westendorp et al. 1995; Ellis et al. 2000; Nath 2002) . High concentrations of HIV-1 Tat levels (>4000 pg/ml) were observed in CSF of HIV infected individuals regardless of viral load . HIV-1 has been shown to increase neuronal Aβ generation (Rempel and Pulliam 2005; Giunta et al. 2009; Aksenov et al. 2010 ) and tau phosphorylation (Giunta et al. 2009; Fields et al. 2015) . HIV-1 Tat enters neurons rapidly by receptor-mediated endocytosis with the assistance of lowdensity lipoprotein receptor-related protein (LRP-1) (Liu et al. 2000; Vendeville et al. 2004; King et al. 2006; Deshmane et al. 2011) . Once endocytosed, HIV-1 Tat accumulates in endolysosomes (Vendeville et al. 2004 ) -acidic organelles where amyloidogenic processing of amyloid beta precursor protein (AβPP) to Aβ occurs in neurons (Rajendran and Annaert 2012; Morel et al. 2013) . We have shown that HIV-1 Tat contributes directly to the development of endolysosome dysfunction in neurons (Hui et al. 2012 ), a common pathological feature present in AD (Cataldo et al. 2000; Tate and Mathews 2006; Boland et al. 2008 ) and in HAND (Gelman et al. 2005; Spector and Zhou 2008; Zhou and Spector 2008) . Furthermore, we have shown that endolysosome dysfunction plays an important role in HIV-1 Tat-induced Aβ generation in neurons (Hui et al. 2012; Chen et al. 2013) .
Caffeine, the most commonly ingested psychoactive drug in the world, has been shown to be protective against AD pathogenesis Arendash and Cao 2010; Eskelinen and Kivipelto 2010; Wostyn et al. 2011; Cao et al. 2012; Carman et al. 2014; Flaten et al . 2014) . Epidemiologically, caffeine ingestion has a reciprocal relationship with the prevalence and severity of AD (Ritchie et al. 2007; Eskelinen et al. 2009; Santos et al. 2010a Santos et al. , 2010b Gelber et al. 2011) . In animal models, caffeine has been shown to prevent AD-like features as well as reverse the features once formed (Arendash et al. 2006 Espinosa et al. 2013; Han et al. 2013; Laurent et al. 2014) . Although different mechanisms underlying the protective actions of caffeine have been implicated, we reported recently that caffeine blocks LDL endocytosis and that this inhibition plays an important role in caffeine's protective effects against LDL-induced neuronal generation of Aβ (Li et al. 2015) . Our findings are consistent with the notion that amyloidogenic processing of AβPP occurs predominantly within endolysosomes after AβPP is internalized (Rajendran and Annaert 2012; Morel et al. 2013) .
Because HIV-1 Tat enters neurons via receptor mediated endocytosis (Liu et al. 2000) and HIV-1 Tat accumulation in endolysosomes affects the morphology and function of these organelles including Aβ generation and tau phosphorylation (Kenessey et al. 1997; Oyama et al. 1998; Hamano et al. 2008; Wang et al. 2009; Hui et al. 2012; Chen et al. 2013; Chesser et al. 2013) , and because our recent finding that caffeine blocks LDL endocytosis and LDL-induced neuronal generation of Aβ (Li et al. 2015) , here we tested the hypothesis that caffeine blocks HIV-1 Tat-induced endolysosome dysfunction and AD-like pathology including Aβ generation and tau phosphorylation.
Material and Methods
Cultures of Human Neuroblastoma Cells Human neuroblastoma cells (SH-SY5Y) expressing wild-type AβPP were kindly supplied by Dr. Norman Haughey (Johns Hopkins, Baltimore, MD). Cells were cultured in Eagle's minimum essential medium (MEM) supplemented with 10 % fetal calf serum, penicillin/streptomycin, nonessential amino acids, and sodium pyruvate (1 mM) at 37°C in 5 % CO 2 /95 % air. For the experiments, 4 × 10 6 cells were seeded on 60 mm 2 dishes and cultured for 48 h. Cells were treated with HIV-1 Tat 1-72 or as a control a mutant form of HIV-1 Tat (Tat Δ31-61 ) for 2 days, in the absence or presence of caffeine. Highly purified recombinant Tat 1-72 and Tat Δ31-61 were prepared as previously described (Ma and Nath 1997) and were kindly provided to us by Dr. Avindra Nath (NINDS).
Quantification of Aβ Levels Secreted and intracellular Aβ levels were measured using human Aβ 1-40 and Aβ 1-42 ELISA kits as per the manufacturer's protocol (Invitrogen, Carlsbad, CA). For secreted Aβ measurements, media from cultured cells was collected, diluted 1:4 with standard diluent buffer, and each sample was analyzed in duplicate. Total cellular protein levels were determined by a DC protein assay (Bio-Rad). Aβ levels were normalized to total protein content in each sample. For intracellular Aβ measurement, cells were trypsinized and collected by centrifugation at 5000 × g and the cell pellet was homogenized thoroughly with 8-times mass of ice-cold 5 M guanidine-HCl/50 mM Tris-HCl. The samples were diluted with ice-cold reaction buffer (Dulbecco's phosphate-buffered saline with 5 % BSA and 0.03 % Tween-20 supplemented with 1 × protease inhibitor cocktail) and centrifuged at 16,000 × g for 20 min at 4°C. The supernatant was collected, diluted at 1:1 with standard diluent buffer, and quantified by colorimetric sandwich ELISA kits. Intracellular Aβ levels were normalized to total protein content in the samples.
Immunoblotting Cells were lysed with RIPA buffer (Pierce) plus 10 mM NaF, 1 mM Na 3 VO 4 and Protease Inhibitor Cocktail (Sigma). After centrifugation (14,000 × g for 10 min at 4°C), supernatants were collected and protein concentrations were determined with a DC protein assay (BioRad). Proteins (10 μg) were separated by SDS-PAGE (12 % gel) and following transfer to polyvinylidene difluoride membranes (Millipore), membranes were incubated overnight at 4°C with antibodies including anti-tau-5 (Abcam), anti-phospho tau (AT8, Thermo Scientific), anti-cathepsin D (Abcam), anti-LAMP-1 (Sigma), and anti-vacuolar-ATPase (Santa Cruz). GAPDH (Abcam) was used as a loading control. The immunoblots were developed with enhanced chemiluminescence, and bands were visualized and analyzed by LabWorks 4.5 software on a UVP Bioimaging System (Upland). Quantification of results was performed by densitometry and the results were analyzed as total integrated densitometric volume values (arbitrary units).
Immunoelution of Tat HIV-1 Tat 1-72 were immunoadsorbed by adding 1:100 (v:v) dilutions of mouse monoclonal antibody raised against the N-terminal portion of the Tat protein bound to protein G-coated agarose beads. Following incubation for 90 min at room temperature, samples were centrifuged at 14,000 × g for 10 min and supernatants were used as controls.
Statistical Analysis All data were expressed as means and SEM values. Statistical significance for multiple comparisons was determined by one-way ANOVA plus a Tukey post hoc test. p < 0.05 was considered to be statistically significant.
Results
Caffeine Blocked HIV-1 Tat-Induced Increases in Aβ Generation and Tau Phosphorylation Consistent with previous findings by others and us that HIV-1 Tat increases neuronal Aβ generation (Rempel and Pulliam 2005; Giunta et al. 2009; Aksenov et al. 2010; Chen et al. 2013 ) and tau phosphorylation (Giunta et al. 2009; Fields et al. 2015) , we demonstrated in SH-SY5Y human neuroblastoma cells over-expressing wildtype AβPP that HIV-1 Tat treatment significantly increased levels of secreted Aβ 1-40 and Aβ 1-42 (Fig. 1a) . The HIV-1 Tat concentration used here is consistent with the Tat levels (>4000 pg/ml) measured in CSF of infected individuals regardless of viral load . To test for HIV-1 Tat specificity, a mutant form of HIV-1 Tat (Tat Δ31-61 ) that is not directly neurotoxic (Buscemi et al. 2007 ) and immunoeluted Tat 1-72 were used as controls and neither significantly affected levels of Aβ (Fig. 1a) . In addition, HIV-1 Tat 1-72 , but not Tat Δ31-61 or immunoeluted Tat 1-72 significantly increased protein levels of phosphorylated tau (Fig. 1b) . In preliminary studies using caffeine at concentrations of 20, 200 and 2000 μM we found 200 μM to be the most effective concentration that consistently and significantly decreased Aβ levels as well as HIV-1 Tat-induced increases in levels of Aβ (data not shown). In the absence of HIV-1 Tat treatment, caffeine (200 μM) significantly decreased secreted levels of Aβ (Fig. 1c) and intracellular levels of Aβ 1-42 (Fig. 1d) . Caffeine (200 μM) blocked HIV-1 Tat-induced increases in levels of secreted Aβ 1-40 and Aβ (Fig. 1c) and levels of intracellular Aβ 1-40 and Aβ (Fig. 1d) . Furthermore, while caffeine (200 μM) alone did not affect protein levels of phosphorylated tau, but it did block HIV-1 Tat-induced increases in tau phosphorylation (Fig. 1e) .
Caffeine Blocked HIV-1 Tat-Induced Endolysosome Dysfunction Consistent with our previous findings that HIV-1 Tat de-acidified endolysosomes (Hui et al. 2012; Chen et al. 2013) , we found here that HIV-1 Tat (100 nM for 2 days) significantly decreased protein levels of vacuolar-ATPase; a major mechanism by which endolysosomes maintain their acidic environment (Fig. 2a) . Caffeine (200 μM) significantly blocked HIV-1 Tat-induced decreases in protein levels of vacuolar-ATPase (Fig. 2a) , but did not by itself affect protein levels of vacuolar-ATPase. In addition, caffeine (200 μM) alone did not affect protein levels of endolysosome enzyme cathepsin D, but did significantly block HIV-1 Tat-induced increases in protein levels of cathepsin D (Fig. 2b) . There appeared to be a trend that caffeine blocks Tat-induced increase in protein levels of lysosome associated membrane protein LAMP-1 (Fig. 2c) , although differences did not reach significant level.
Discussion
HIV-1 virus does not infect neurons, and HIV-associated neurodegenerative pathology is not proportional to viral load (van de Bovenkamp et al. 2002) . Thus, HIV-1 viral proteins and other factors have been implicated in the neurological complications associated with HIV-1 infections. Among HIV-1 viral proteins, HIV-1 Tat is present in brains of HIV-1 infected individuals and its levels stay elevated in CSF even when HIV-1 viral levels are immeasurable ). Others and we have shown consistently that HIV-1 Tat is neurotoxic and it continues to be linked to the pathogenesis of HAND (Nuovo et al. 1994; Nath et al. 1996; Merino et al. 2011) . Increasingly, HIV-1 infection and ART treatment has been shown to contribute to the development of AD-like pathology including increases in Aβ levels (Rempel and Pulliam 2005; Giunta et al. 2009; Aksenov et al. 2010; Chen et al. 2013; Kim et al. 2013; Fields et al. 2015) . Of mechanistic significance, we have shown that HIV-1 Tat-induced endolysosome dysfunction following receptor-mediated endocytosis underlies HIV-1 Tat-induced increases in neuronal generation of Aβ (Hui et al. 2012; Chen et al. 2013) . Here, we demonstrated that caffeine, a protective agent against AD, blocks HIV-1 Tat-induced increases in Aβ generation and tau phosphorylation as well as decreases in protein levels of vacuolar-ATPase. Our findings suggest that caffeine exerts it protective effects against the development of AD-like pathology, in part, by blocking HIV-1 Tatinduced endolysosome dysfunction.
Endolysosomes are acidic organelles that contain various pH-dependent lytic enzymes and vacuolar H + -ATPase helps maintain an acidic environment necessary for maintenance of protein turnover and cellular homeostasis (Appelqvist et al. 2013) . Indeed, endolysosomes have been implicated in the pathogenesis of sporadic AD (Tate and Mathews 2006; Boland et al. 2008) and HAND (Gelman et al. 2005; Spector and Zhou 2008; Zhou and Spector 2008; Cysique et al. 2015) . Neurons, as long-lived post-mitotic cells, are especially vulnerable to perturbations of endolysosome pH and by maintaining an acidic environment endolysosomes are able to control the integrity of quality of critical proteins (Nixon and Cataldo 1995; Bonaldo and Sandri 2013) . Endolysosome dysfunction has been implicated in the development of the two pathological hallmarks of AD; Aβ accumulation and neurofibrillary tangle formation. Following endocytosis of AβPP, a ubiquitously expressed type-I transmembrane protein with largely uncharacterized physiological functions, amyloidogenic processing of AβPP occurs (Rajendran and Annaert 2012; Morel et al. 2013; Jiang et al. 2014) because this is where the amyloidogenic enzymes BACE-1 and γ-secretase are almost exclusively located. The acidic environment of endolysosomes is favorable for amyloidogenic metabolism of AβPP (Nixon 2005; Rajendran et al. 2008; Shimizu et al. 2008; Sannerud et al. 2011 ) and once formed Aβ can either accumulate in endolysosomes or following exocytotic release it can alone did not affect tau phosphorylation, but blocked HIV-1 Tat (100 nM for 2 days) induced increases in tau phosphorylation (n = 4). One-way ANOVA with a Tukey post-hoc test was for statistical analysis accumulate extracellularly. Thus, Aβ accumulation can be enhanced by factors that promote AβPP internalization (Grbovic et al. 2003) , that enhance protein levels and/or activities of BACE-1 and/or γ-secretase, that prevent AβPP recycling back to the cell surface (Ma et al. 2009) , and that impair Aβ degradation by lysosome-resident cathepsins (Miners et al. 2011) ; (Torres et al. 2012) . Tau is a microtubule-associated protein, and when hyperphosphorylated it aggregates and contributes to the formation of neurofibrillary tangles. Tau aggregates can be degraded by cathepsin D in autophagosomes-lysosomes (Hamano et al. 2008; Chesser et al. 2013 ). Thus, endolysosome dysfunction can contribute to tau aggregation and neurofibrillary tangle formation (Jo et al. 2014) ; (Bi and Liao 2007) , and transcriptional activation of lysosome biogenesis can clear aggregated tau (Polito et al. 2014) .
HIV-1 Tat enters neurons via receptor-mediated endocytosis mainly with the assistance of LRP-1 (Liu et al. 2000; Deshmane et al. 2011) . Once endocytosed, HIV-1 Tat can accumulate into and exit from endolysosomes (Vendeville et al. 2004 ). Further, we have shown that HIV-1 Tat can directly affect morphological and functional features of neuronal endolysosomes including endolysosome de-acidification and endolysosome enlargement (Hui et al. 2012) , indicating that HIV-1 Tat has a direct effect on endolysosome structure and function. Here, we demonstrated, in AβPP overexpressing SH-SY5Y cells, that HIV-1 Tat decreased protein levels of vacuolar-ATPase, the proton pump that is essential for maintaining the acidic environment of endolysosomes. Thus, endolysosome de-acidification by HIV-1 Tat might be caused by decreased vacuolar-ATPase. The HIV-1 Tat-induced decreases in vacuolar-ATPase and endolysosome deacidification might then cause compensatory increases in cathepsin D and LAMP-1 (Mangieri et al. 2014 ), as we observed in these studies. Although SH-SY5Y cells over-expressing human AβPP are human Aβ processing neuronal cell cultures that are commonly used in AD-related studies, this nonphysiological over-expression of AβPP may not fully reconstitute pathogenic cascades of HAND and may lead to supplementary pathogenic effects in addition to the accumulation of Aβ. However, we did observe similar Tat-induced endolysosome dysfunction and AD-like pathology in primary cultured neurons (Hui et al. 2012; Chen et al. 2013) .
Consistent with our previous findings in primary cultured neurons showing that HIV-1 Tat altered structural and functional features of endolysosomes and increased endolysosome accumulation of Aβ (Chen et al. 2013) , we demonstrated here using SH-SY5Y cells over-expressing AβPP that HIV-1 Tat increased levels of secreted Aβ as well as increased accumulation of intracellular Aβ. LRP-1, a promiscuous receptor that mediates HIV-1 Tat endocytosis, has been shown by others and us to interact physically and functionally with AβPP (Waldron et al. 2006 (Waldron et al. , 2008 Klug et al. 2011 ) to increase HIV-1 Tat and AβPP internalization (Chen et al. 2013) . Once internalized into acidic endosomes, AβPP can be cleaved by β-and γ-secretase to form Aβ. The increased Aβ production may also have been due to HIV-1 Tat-induced increases in protein levels of AβPP and BACE-1 and/or alternatively to HIV-1 Tat-induced endolysosome dysfunction; both are highly likely explanations because endolysosomes play a critical role in Aβ generation (Rajendran and Annaert 2012; Morel et al. 2013; Jiang et al. 2014) . HIV-1 Tat-induced endolysosome dysfunction may also contribute to increases in tau phosphorylation. Because tau and phosphorylated tau can be degraded in autophagosomes and lysosomes (Chesser et al. 2013; Jo et al. 2014) , endolysosome dysfunction and impaired lysosome degradation following HIV-1 Tat endocytosis could lead to accumulations of phosphorylated tau and the development of neurofibrillary tangles.
Our findings suggest that HIV-1 Tat induced endolysosome dysfunction may play an important role in HIV-1 Tat-induced AD-like pathology. As such, attenuating endolysosome function may present an effective strategy against HIV-1 Tat-induced increases in Aβ generation and tau phosphorylation. Based on our recent findings that caffeine inhibits LDL endocytosis and LDL-induced Aβ generation in neurons (Li et al. 2015) , we examined the effects of caffeine on HIV-1 Tat-induced increases in Aβ generation and tau phosphorylation. We demonstrated that caffeine blocked HIV-1 Tat induced endolysosome dysfunction as well as AD-like pathological features including increases in levels of secreted Aβ, intracellular accumulation of Aβ, and increased levels of phosphorylated tau. Our findings suggest that caffeine could prevent HIV-1 Tat-induced AD-like pathology in part by preventing HIV-1 Tat-induced endolysosome dysfunction. It is estimated that 1 cup of coffee consumption (40-100 mg of caffeine) can result in plasma concentrations of free caffeine of about 1-10 μM (Fredholm et al. 1999 ). However, because caffeine is highly protein bound, total plasma caffeine concentrations would be much higher (Blanchard 1982) . Caffeine concentrations used in this study (200 μM) are in the upper range of plasma concentrations of caffeine (Fredholm et al. 1999) . Indeed, we confirmed in a previous study that 200 μM of caffeine does not have neurotoxic effects (Li et al. 2015) .
In short, our findings add to the ever-increasing reports that caffeine provides robust protective actions against AD. Besides its protective role against the development of AD, caffeine has been shown to exert protective effect against HIV-1 pathogenesis Nunnari et al. 2005) . Thus, caffeine might be used in the treatment of AD-like symptoms and neuropathology associated with HIV-1 infection.
